Table 7.

Summary of treatment discontinuation/change and adverse events by most common type across manifestations

Manifestation	Discontinued/change in treatment	Bone marrow suppression	Gastrointestinal	Dermatologic
Ocular toxoplasmosis
Frequency by study	11/11 (100%)	4/11 (36.4%)	4/11 (36.4%)	7/11 (63.6%)
Prevalence, range	2.2–26%	2.8–9.0%	4.2–100%	0.3–11.1%
Toxoplasmic encephalitis
Frequency by study	4/7 (57.1%)	5/7 (71.4%)	2/7 (28.6%)	4/7 (57.1%)
Prevalence, range	12.1–32.1%	6.6–42.7%	3.4–10.7%	6.3–17.9%
Congenital toxoplasmosisa
Frequency by study	8/13 (61.5%)	10/13 (76.9%)	3/13 (23.1%)	4/13 (30.8%)
Prevalence, range	1.8–50%	0.8–50%	0.8–10.8%	0.8–2.1%

^aValues represent only data from infants